

Erratum to: Reslizumab: First Global Approval

Anthony Markham¹

Published online: 28 June 2016
© Springer International Publishing Switzerland 2016

Erratum to: Drugs (2016) 76(8):907–911
DOI 10.1007/s40265-016-0583-2

Page 908, table entitled ‘Features and properties of reslizumab’

The third row, Mechanism of Action, which previously read:

Interleukin 5 receptor antagonist

Should read:

Interleukin 5 inhibitor

The online version of the original article can be found under
doi:[10.1007/s40265-016-0583-2](https://doi.org/10.1007/s40265-016-0583-2).

✉ Anthony Markham
dru@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland,
New Zealand